The advent of targeted therapy has revolutionized the field of oncology, offering a more personalized approach to cancer treatment. Unlike conventional chemotherapy, which indiscriminately targets rapidly dividing cells, targeted therapies aim to interfere with specific molecules necessary for tumor growth and progression.
Targeted therapies can be broadly classified into two categories: small molecules and monoclonal antibodies. Small molecules are low-weight compounds that can penetrate the cell membrane and interact with intracellular targets. Monoclonal antibodies, on the other hand, are large proteins that cannot cross the cell membrane and are designed to target extracellular or cell surface molecules.
Targeted therapies work by blocking the growth signals of cancer cells, interfering with angiogenesis, promoting apoptosis, or enhancing the immune response against cancer cells. They have the advantage of being more selective, hence causing fewer side effects than traditional chemotherapy.
Despite the promising results of targeted therapies, challenges remain. These include the development of resistance, the high cost of these therapies, and the difficulty in identifying appropriate molecular targets. However, ongoing research and technological advancements promise to overcome these obstacles and broaden the application of targeted therapies in cancer treatment.
Targeted therapy represents a significant advancement in modern oncology, offering a more tailored approach to cancer treatment. By specifically targeting cancer cells, these therapies minimize damage to healthy cells and reduce side effects. Despite existing challenges, the potential of targeted therapies is vast and continues to be explored in ongoing research. As healthcare professionals, staying abreast of these developments is crucial to provide the best care for our patients.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation